The Australian healthcare sector continues to attract investor attention as companies progress from early development into clinical validation, regulatory approval, and commercial execution. This ASX Companies Snapshot & Market Position provides a concise, side-by-side overview of selected ASX-listed healthcare companies, outlining what each business does, where it sits within the market, and how it is currently positioned from a market capitalisation and execution perspectiv

Actinogen Medical (ASX: ACW) released two important updates dated 20 October 2025: (1) accelerated recruitment has enabled early closure of pTau screening for the Phase 2b/3 XanaMIA Alzheimer’s trial; and (2) an Advance Overseas Finding (AOF) approval confirms eligibility for a further RDTI rebate of ~$1.87m, taking the total FY25 RDTI to ~$7.36m if the ATO amendment is favourably assessed.